Kura Oncology Statistics

Total Valuation

Kura Oncology has a market cap or net worth of $564.56 million. The enterprise value is $125.90 million.

Market Cap	564.56M
Enterprise Value	125.90M

Important Dates

The next estimated earnings date is Tuesday, February 25, 2025, after market close.

Earnings Date	Feb 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Kura Oncology has 77.76 million shares outstanding. The number of shares has increased by 18.20% in one year.

Current Share Class	77.76M
Shares Outstanding	77.76M
Shares Change (YoY)	+18.20%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	0.85%
Owned by Institutions (%)	78.02%
Float	49.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.33
P/TBV Ratio	1.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.47, with a Debt / Equity ratio of 0.04.

Current Ratio	11.47
Quick Ratio	11.39
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-135.09

Financial Efficiency

Return on equity (ROE) is -46.28% and return on invested capital (ROIC) is -30.63%.

Return on Equity (ROE)	-46.28%
Return on Assets (ROA)	-28.54%
Return on Capital (ROIC)	-30.63%
Revenue Per Employee	n/a
Profits Per Employee	-$1.39M
Employee Count	142
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -52.14% in the last 52 weeks. The beta is 0.80, so Kura Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-52.14%
50-Day Moving Average	11.19
200-Day Moving Average	17.78
Relative Strength Index (RSI)	19.21
Average Volume (20 Days)	1,737,089

Short Selling Information

The latest short interest is 10.44 million, so 13.42% of the outstanding shares have been sold short.

Short Interest	10.44M
Short Previous Month	8.89M
Short % of Shares Out	13.42%
Short % of Float	21.07%
Short Ratio (days to cover)	5.80

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-217.50M
Pretax Income	-181.75M
Net Income	-197.55M
EBITDA	-216.64M
EBIT	-217.50M
Earnings Per Share (EPS)	-$2.36

Full Income Statement

Balance Sheet

The company has $455.30 million in cash and $16.63 million in debt, giving a net cash position of $438.67 million or $5.64 per share.

Cash & Cash Equivalents	455.30M
Total Debt	16.63M
Net Cash	438.67M
Net Cash Per Share	$5.64
Equity (Book Value)	423.77M
Book Value Per Share	5.45
Working Capital	422.82M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$169.12 million and capital expenditures -$116,000, giving a free cash flow of -$169.24 million.

Operating Cash Flow	-169.12M
Capital Expenditures	-116,000
Free Cash Flow	-169.24M
FCF Per Share	-$2.18

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.20%
Shareholder Yield	-18.20%
Earnings Yield	-34.99%
FCF Yield	-29.98%

Analyst Forecast

The average price target for Kura Oncology is $27.89, which is 284.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$27.89
Price Target Difference	284.16%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2